290 related articles for article (PubMed ID: 24304415)
21. Molecular basis of adrenocortical carcinomas.
Soon PS; Sidhu SB
Minerva Endocrinol; 2009 Jun; 34(2):137-47. PubMed ID: 19471238
[TBL] [Abstract][Full Text] [Related]
22. Molecular markers and the pathogenesis of adrenocortical cancer.
Soon PS; McDonald KL; Robinson BG; Sidhu SB
Oncologist; 2008 May; 13(5):548-61. PubMed ID: 18515740
[TBL] [Abstract][Full Text] [Related]
23. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
[TBL] [Abstract][Full Text] [Related]
24. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
[TBL] [Abstract][Full Text] [Related]
25. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
Gaujoux S; Pinson S; Gimenez-Roqueplo AP; Amar L; Ragazzon B; Launay P; Meatchi T; Libé R; Bertagna X; Audebourg A; Zucman-Rossi J; Tissier F; Bertherat J
Clin Cancer Res; 2010 Nov; 16(21):5133-41. PubMed ID: 20978149
[TBL] [Abstract][Full Text] [Related]
26. New targeted therapies for adrenocortical carcinomas.
Manso J; Pezzani R
Minerva Endocrinol; 2019 Mar; 44(1):70-81. PubMed ID: 29808641
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2012 Nov; 364(1-2):101-4. PubMed ID: 22960230
[TBL] [Abstract][Full Text] [Related]
28. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients.
Chabre O; Libé R; Assie G; Barreau O; Bertherat J; Bertagna X; Feige JJ; Cherradi N
Endocr Relat Cancer; 2013 Aug; 20(4):579-94. PubMed ID: 23756429
[TBL] [Abstract][Full Text] [Related]
29. Current Status and Future Targeted Therapy in Adrenocortical Cancer.
Alyateem G; Nilubol N
Front Endocrinol (Lausanne); 2021; 12():613248. PubMed ID: 33732213
[TBL] [Abstract][Full Text] [Related]
30. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
[TBL] [Abstract][Full Text] [Related]
31. Liposomal doxorubicin-based treatment in a preclinical model of adrenocortical carcinoma.
Hantel C; Lewrick F; Reincke M; Süss R; Beuschlein F
J Endocrinol; 2012 May; 213(2):155-61. PubMed ID: 22407999
[TBL] [Abstract][Full Text] [Related]
32. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007
[TBL] [Abstract][Full Text] [Related]
33. 5th International ACC Symposium: An Outlook to Current and Future Research on the Biology of Adrenocortical Carcinoma: Diagnostic and Therapeutic Applications.
Lalli E; Sasano H
Horm Cancer; 2016 Feb; 7(1):44-8. PubMed ID: 26666256
[TBL] [Abstract][Full Text] [Related]
34. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.
Nakamura Y; Yamazaki Y; Felizola SJ; Ise K; Morimoto R; Satoh F; Arai Y; Sasano H
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):399-410. PubMed ID: 26038208
[TBL] [Abstract][Full Text] [Related]
35. 5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma.
Hoff AO; Berruti A
Horm Cancer; 2016 Feb; 7(1):29-35. PubMed ID: 26728470
[TBL] [Abstract][Full Text] [Related]
36. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.
Satoh K; Zhang L; Zhang Y; Chelluri R; Boufraqech M; Nilubol N; Patel D; Shen M; Kebebew E
Clin Cancer Res; 2016 Jul; 22(14):3458-66. PubMed ID: 26873959
[TBL] [Abstract][Full Text] [Related]
37. Update on adrenocortical carcinoma management and future directions.
Varghese J; Habra MA
Curr Opin Endocrinol Diabetes Obes; 2017 Jun; 24(3):208-214. PubMed ID: 28277340
[TBL] [Abstract][Full Text] [Related]
38. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.
De Martino MC; van Koetsveld PM; Feelders RA; de Herder WW; Dogan F; Janssen JAMJL; Hofste Op Bruinink D; Pivonello C; Waaijers AM; Colao A; de Krijger RR; Pivonello R; Hofland LJ
Endocrine; 2019 Jun; 64(3):673-684. PubMed ID: 30838516
[TBL] [Abstract][Full Text] [Related]
39. Current Prospects for Adrenocortical Carcinoma Pharmacotherapy.
Ławnicka H
Recent Pat Anticancer Drug Discov; 2023; 18(1):29-37. PubMed ID: 36482727
[TBL] [Abstract][Full Text] [Related]
40. 5th International ACC Symposium: Old Syndromes with New Biomarkers and New Therapies with Old Medications.
Rao SN; Habra MA
Horm Cancer; 2016 Feb; 7(1):17-23. PubMed ID: 26660146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
